Goldman Sachs analyst Paul Choi downgraded Edgewise Therapeutics (EWTX) to Neutral from Buy with a $20 price target
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EWTX:
- JPMorgan cuts Edgewise target, remains from Analyst Focus List
- Edgewise Therapeutics Advances in Muscular Dystrophy Trials
- Edgewise Therapeutics: Strong Financial Health and Promising Clinical Advances Drive Buy Rating
- Edgewise Therapeutics reports Q2 EPS (34c), consensus (42c)
- Peloton upgraded, Booking downgraded: Wall Street’s top analyst calls